Compare TRST & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRST | PHAT |
|---|---|---|
| Founded | 1902 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 858.9M | 894.0M |
| IPO Year | 1994 | 2019 |
| Metric | TRST | PHAT |
|---|---|---|
| Price | $50.25 | $11.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | 67.4K | ★ 1.3M |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.25% | N/A |
| EPS Growth | 26.46 | ★ 42.72 |
| EPS | ★ 0.91 | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | N/A | $58.91 |
| P/E Ratio | $55.44 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $30.17 | $3.92 |
| 52 Week High | $50.52 | $18.31 |
| Indicator | TRST | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 67.76 | 43.75 |
| Support Level | $41.96 | $11.04 |
| Resistance Level | N/A | $12.83 |
| Average True Range (ATR) | 0.89 | 0.73 |
| MACD | 0.11 | -0.13 |
| Stochastic Oscillator | 82.95 | 8.04 |
Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The company derives revenue from the business of Banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey, and Vermont.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.